Blood pressure and cardiovascular effects of new and emerging antidiabetic agents

Pelbreton C. Balfour, Carlos J. Rodriguez, Keith C. Ferdinand

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Despite remarkable declines in US cardiovascular disease morbidity and mortality over the last several decades, the prevalence of risk factors such as type 2 diabetes and hypertension remains high, associated with increasing obesity rates. Although optimal glycemic control remains a primary focus to decrease the disease burden, the FDA has issued guidance recommendations for documenting cardiovascular disease-related safety with research trials on new antidiabetic agents with more demanding requirements compared to past approval of existing therapies. This review will discuss the public health impact of type 2 diabetes, specifically with comorbid hypertension; mechanisms of action of the newest antidiabetic drug classes; and preliminary findings and potential clinical significance of the favorable blood pressure and body weight effects of the sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists; and additionally discuss two recent large cardiovascular outcome trials with dipeptidyl peptidase-4 inhibitors.

Original languageEnglish (US)
Article number455
JournalCurrent Hypertension Reports
Volume16
Issue number8
DOIs
StatePublished - Aug 2014
Externally publishedYes

Fingerprint

Hypoglycemic Agents
Type 2 Diabetes Mellitus
Cardiovascular Diseases
Sodium-Glucose Transport Proteins
Dipeptidyl-Peptidase IV Inhibitors
Blood Pressure
Hypertension
Public Health
Obesity
Body Weight
Morbidity
Safety
Mortality
Research
Therapeutics
Glucagon-Like Peptide-1 Receptor

Keywords

  • Antidiabetic drugs
  • Cardiovascular disease
  • Diabetes
  • Dipeptidyl peptidase-4 inhibitors
  • Glucagon-like peptide-1 receptor agonists
  • Hypertension
  • Obesity
  • Sodium-glucose cotransporter 2 inhibitors
  • Systolic blood pressure

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Blood pressure and cardiovascular effects of new and emerging antidiabetic agents. / Balfour, Pelbreton C.; Rodriguez, Carlos J.; Ferdinand, Keith C.

In: Current Hypertension Reports, Vol. 16, No. 8, 455, 08.2014.

Research output: Contribution to journalReview article

@article{5ae1e9e97b97462aa8551cca50de3bee,
title = "Blood pressure and cardiovascular effects of new and emerging antidiabetic agents",
abstract = "Despite remarkable declines in US cardiovascular disease morbidity and mortality over the last several decades, the prevalence of risk factors such as type 2 diabetes and hypertension remains high, associated with increasing obesity rates. Although optimal glycemic control remains a primary focus to decrease the disease burden, the FDA has issued guidance recommendations for documenting cardiovascular disease-related safety with research trials on new antidiabetic agents with more demanding requirements compared to past approval of existing therapies. This review will discuss the public health impact of type 2 diabetes, specifically with comorbid hypertension; mechanisms of action of the newest antidiabetic drug classes; and preliminary findings and potential clinical significance of the favorable blood pressure and body weight effects of the sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists; and additionally discuss two recent large cardiovascular outcome trials with dipeptidyl peptidase-4 inhibitors.",
keywords = "Antidiabetic drugs, Cardiovascular disease, Diabetes, Dipeptidyl peptidase-4 inhibitors, Glucagon-like peptide-1 receptor agonists, Hypertension, Obesity, Sodium-glucose cotransporter 2 inhibitors, Systolic blood pressure",
author = "Balfour, {Pelbreton C.} and Rodriguez, {Carlos J.} and Ferdinand, {Keith C.}",
year = "2014",
month = "8",
doi = "10.1007/s11906-014-0455-7",
language = "English (US)",
volume = "16",
journal = "Current Hypertension Reports",
issn = "1522-6417",
publisher = "Current Medicine Group",
number = "8",

}

TY - JOUR

T1 - Blood pressure and cardiovascular effects of new and emerging antidiabetic agents

AU - Balfour, Pelbreton C.

AU - Rodriguez, Carlos J.

AU - Ferdinand, Keith C.

PY - 2014/8

Y1 - 2014/8

N2 - Despite remarkable declines in US cardiovascular disease morbidity and mortality over the last several decades, the prevalence of risk factors such as type 2 diabetes and hypertension remains high, associated with increasing obesity rates. Although optimal glycemic control remains a primary focus to decrease the disease burden, the FDA has issued guidance recommendations for documenting cardiovascular disease-related safety with research trials on new antidiabetic agents with more demanding requirements compared to past approval of existing therapies. This review will discuss the public health impact of type 2 diabetes, specifically with comorbid hypertension; mechanisms of action of the newest antidiabetic drug classes; and preliminary findings and potential clinical significance of the favorable blood pressure and body weight effects of the sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists; and additionally discuss two recent large cardiovascular outcome trials with dipeptidyl peptidase-4 inhibitors.

AB - Despite remarkable declines in US cardiovascular disease morbidity and mortality over the last several decades, the prevalence of risk factors such as type 2 diabetes and hypertension remains high, associated with increasing obesity rates. Although optimal glycemic control remains a primary focus to decrease the disease burden, the FDA has issued guidance recommendations for documenting cardiovascular disease-related safety with research trials on new antidiabetic agents with more demanding requirements compared to past approval of existing therapies. This review will discuss the public health impact of type 2 diabetes, specifically with comorbid hypertension; mechanisms of action of the newest antidiabetic drug classes; and preliminary findings and potential clinical significance of the favorable blood pressure and body weight effects of the sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists; and additionally discuss two recent large cardiovascular outcome trials with dipeptidyl peptidase-4 inhibitors.

KW - Antidiabetic drugs

KW - Cardiovascular disease

KW - Diabetes

KW - Dipeptidyl peptidase-4 inhibitors

KW - Glucagon-like peptide-1 receptor agonists

KW - Hypertension

KW - Obesity

KW - Sodium-glucose cotransporter 2 inhibitors

KW - Systolic blood pressure

UR - http://www.scopus.com/inward/record.url?scp=84901859345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901859345&partnerID=8YFLogxK

U2 - 10.1007/s11906-014-0455-7

DO - 10.1007/s11906-014-0455-7

M3 - Review article

C2 - 24908134

AN - SCOPUS:84901859345

VL - 16

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - 8

M1 - 455

ER -